MMJ BioScience Announces Partnership with Pharmaceutical Manufacturing Company To Supply Cannabis Medicine For Multiple Sclerosis Study

MMJ BioScience Files Pre Investigational New Drug (IND) Application With FDA For Pharmaceutical Cannabidiol (CBD) derived medicine.
December 12, 2017
MMJ International Holdings Files US Patent Prior to FDA Study for Cannabinoid Treatment Medicine
January 8, 2018

MMJ BioScience Announces Partnership with Pharmaceutical Manufacturing Company To Supply Cannabis Medicine For Multiple Sclerosis Study

MMJ Bioscience now offers excellence in cannabinoid medicine manufacturing thats solves dosing issues by utilizing various delivery systems. Those delivery systems include softgels, liquids, topicals, sprays and liposomes, with capabilities for quick release, sustained release and targeted release of medicine. The MMJ Group is focused on scientific research, collaboration and has filed a FDA application to begin clinical trials to fully explore the potential of cannabis medicine for progressive multiple sclerosis patients.

MMJ International Holdings, a premier medical cannabis research company, is advancing the science of medical marijuana through patient clinical research and the operation of medical cannabis healthcare businesses, announced that its affiliate,

MMJ Bioscience, has finalized a partnership agreement with Terra Life Science group, a private Canadian based pharmaceutical manufacturer, to produce cannabis medicines for the groups FDA approved studies.

Under the terms of the Agreement,Terra Life Sciences subsidiary, Olds SoftGels Inc, will produce MMJ BioSciences proprietary pharma-grade cannabis and CBD based medicine. The group has production capacity of over 2.5 billion softgel capsules a year manufactured from two FDA and Health Canada approved facilities. This agreement uniquely positions MMJ BioScience with the capacity to develop innovative, pharmaceutical grade cannabis and CBD based medicines from a GMP (Good Manufacturing Practice) facility who’s manufacturing systems will ensure that products are consistently produced and controlled according to FDA quality standards.

Tim Moynahan, MMJ BioSciences chairman, stated “We are excited to be a partner with Terra Life Sciences. This agreement enables MMJ BioScience a significant product development capability. We anticipate a number of important synergies between the two companies that will be addressing patients needs with MMJ BioScience’s FDA multiple sclerosis study.”

As a result of this agreement, MMJ Bioscience now offers excellence in cannabinoid medicine manufacturing that solves dosing issues by utilizing various delivery systems such as softgels, liquids, topicals, sprays and liposomes, with capabilities for quick release, sustained release and targeted release of medicine. The MMJ Group is focused on scientific research, collaboration and has filed a FDA application to begin clinical trials to fully explore the potential of cannabis medicine for progressive multiple sclerosis patients.

Tim Moynahan further stated “The seasoned leadership team at MMJ BioSciences understands and executes its progressive development strategy in a legal, regulatory and fiscally responsible manner in this emerging market. Our company’s success is the result of our focus on identifying patient medical needs and addressing these patients needs by developing medicines from the cannabis plant”.